Imaging and Liquid Biopsy Biomarkers for Cancer Diagnosis and Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 397
Special Issue Editors
Interests: biomedical imaging; quantitative imaging biomarkers; MRI for breast cancer treatment response
Special Issue Information
Dear Colleagues,
Biomarkers are essential for cancer diagnosis and treatment. Imaging and liquid biopsy are both noninvasive methods that can be used to extract quantitative biomarkers repeatedly. A liquid biopsy involves testing blood and other bodily fluids for diagnostic and therapeutic purposes. In the past, imaging has mostly been used to measure tumor size. Recently, radiomics and machine learning (ML)/ deep learning (DL) methods have been developed to study tumor heterogeneity. Imaging focuses on the tumor extent and heterogeneity measurement, while liquid biopsy detects tumor-derived molecules in circulation. In this Special Issue, we are interested in manuscripts that report work combining both imaging and liquid biopsy to diagnosis or treat various kinds of cancer. Imaging modalities include, but are not limited to, magnetic resonance imaging (MRI), X-Ray imaging, computed tomography (CT), ultrasound, and nuclear medicine scans. The liquid biopsy includes tests that can evaulate circulating tumor cells (CTC), disseminated tumor cells (DTC), and circulating tumor DNA or RNA (ctDNA, ctRNA). We welcome original research articles or comprehensive review articles focusing on the combination of quantitative imaging and liquid biopsy biomarkers for cancer detection, staging, prognosis, or monitoring treatment response.
Dr. Wen Li
Dr. Mark Jesus M. Magbanua
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer imaging
- liquid biopsy
- cancer diagnosis
- treatment response
- prognosis
- metastasis
- circulating tumor cells
- disseminated tumor cells
- circulating tumor DNA
- circulating tumor RNA
